Regulatory FDA weighs drug repurposing pathway for underserved diseases Pharmaceutical TechnologyApproved drugs could be expanded into disease areas with limited commercial potential, providing supporting data is available.Read full story pharminent May 12, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology Approved drugs could be expanded into disease areas with limited commercial potential, providing supporting data is available. Read full story Post navigation Previous: Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunitiesNext: A year after Vertex’s big launch, pain drug research faces a pivotal moment Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026